<DOC>
	<DOCNO>NCT01967251</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , dose-response safety udenafil 25 mg , 50 mg 75 mg every day ( q.d . ) 12 week treatment low urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH treatment erectile dysfunction ( ED ) .</brief_summary>
	<brief_title>Efficacy , Safety Dose-response Udenafil Patients With Benign Prostatic Hyperplasia Erectile Dysfunction</brief_title>
	<detailed_description>The drug test study call Udenafil . Udenafil test treat lower urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH ) treatment erectile dysfunction ( ED ) . This study look change lower urinary tract symptom ( LUTS ) associate benign prostatic hyperplasia ( BPH ) erectile dysfunction ( ED ) people take Udenafil . The study enroll approximately 950 patient . Participants take BPH ED medication enter 4-week wash period . Patients previously treat accomplished wash period enter placebo ( dummy inactive pill ) lead-in period another 4 week . Participants randomly assign ( chance , like flip coin ) one four treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Udenafil 25 mg - Udenafil 50 mg - Udenafil 75 mg - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient All participants ask take one tablet time day throughout study , ask keep Sexual Encounter Profile ( SEP ) diary . This multi-centre trial conduct Mexico . The overall time participate study 20 week . Participants make 6 visit clinic .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>1 . Men ≥ 45 year age . 2 . Sexually active , stable female partner participant expect relationship entire duration study . 3 . The participant benign prostatic hyperplasia lower urinary tract symptom ( BPHLUTS ) accord clinical diagnostic criterion , ≥ 6 month evolution screen visit . 4 . Clinical history erectile dysfunction ( ED ) ( define inability achieve maintain penile erection achieve satisfactory sexual relationship ) least 3 month evolution . 5 . Freely give informed consent screen visit ( essential requirement participate study ) . 6 . Bladder obstruction define maximal flow rate ( Qmax ) 415 mI/sec ( premicturition volume 150 550 mL evaluate ultrasound , minimum micturition volume 125 mL ) Visit I immediately prior active treatment initiation . 7 . Total score ≥ 13 point InternationaI Prostate Symptom Score ( IPSS ) questionnaire Visit 1 , immediately prior active treatment initiation . 1 . Participants currently take nitrate , antiandrogens , estrogen , luteninizing hormonereleasing hormone agonist/antagonist , anabolic steroid study entry . Participants take stable dose level testosterone exclude . 2 . Postvoid residual ( PVR ) volume ≥ 300 mL , assess ultrasound Visit 1 . 3 . Prostatespecific antigen ( PSA ) ≥ 10.0 ng/mL Visit 1 . 4 . PSA 4.0 10.0 ng/ml free PSA &lt; 0,25 ( 25 % ) Visit 1 . 5 . Clinical evidence prostate cancer . 6 . Glycosylated hemoglobin ( Hb1Ac ) &gt; 10 % study entry . 7 . Patients undergone bladder catheterization due acute urine retention . 8 . Medical history clinical evidence pelvic , bladder urinary tract condition , urinary retention , judge urologist , might compromise protocol compliance . 9 . Any surgical procedure lower urinary tract ( include prostate biopsy ) within 30 day prior Screening Visit .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Prostatic Hyperplasia</keyword>
	<keyword>Phosphodiesterase 5 inhibitor</keyword>
	<keyword>Erectile DysfunctionDrug Therapy</keyword>
</DOC>